Lv11
22 积分 2022-06-01 加入
Vedolizumab for the Treatment of IBD: A Selective Therapeutic Approach Targeting Pathogenic a4b7 Cells
7小时前
待确认
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
24天前
已完结
The next generation of immunotherapies for lung cancers
28天前
已完结
A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
30天前
已完结
Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs
1个月前
已完结
Combination of immune checkpoint inhibitors and anti-angiogenic agents: An emerging strategy for cancer therapy
1个月前
已完结
Linking tumour angiogenesis and tumour immunity
1个月前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
1个月前
已完结
Sequencing Systemic Therapy in Hepatocellular Carcinoma
1个月前
已完结
Targeted protein degradation in the transmembrane and extracellular space
2个月前
已完结
皖公网安备34019202002308
